

**CLEARBRIDGE HEALTH LIMITED**  
(Incorporated in the Republic of Singapore)  
(Company Registration No. 201001436C)

---

**FURTHER UPDATE ON LEGAL PROCEEDINGS AGAINST FORMER DIRECTORS  
OF AN INDIRECT SUBSIDIARY IN INDONESIA**

---

The Board of Directors (“**Board**” or **Directors**”) of Clearbridge Health Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to the announcements dated 10 June 2020, 16 June 2020, and 9 March 2022 (collectively, the “**Announcements**”) relating to legal proceedings commenced by the Company's indirect subsidiary, PT Tirta Medika Jaya (“**TMJ**”) in the District Court of South Jakarta against its former directors Sam Pranoto, Andreas Kuntjoro Mukri and David Sahputra Hadiwibowo (collectively, the “**Defendants**”). Unless otherwise defined, capitalised terms in this announcement shall have the same meaning as ascribed to them in the Announcements.

The Group wishes to announce that on 19 August 2022, the Bailiff of the District Court of South Jakarta served on TMJ the official notification of appeal submitted by the Defendants in Civil Case No. 433/Pdt.G/2020/PN.Jkt.Sel. (the “**Appeal**”). In addition, TMJ has also been advised by its Indonesian legal counsel that in the event that the Appeal succeeds, the Jakarta High Court could cancel the decision of the South Jakarta District Court, which gave oral judgement on 8 March 2022, in favour of TMJ, for the reasons that it has been proven that the Defendants have committed an unlawful act due to their failure to carry out their fiduciary duties in their management of TMJ. Towards the decision of the Jakarta High Court, if any, both parties Defendants and TMJ will have the right to file an appeal to the Indonesian Supreme Court.

TMJ is currently seeking legal advice on this matter and the Company will update shareholders and potential investors of the Company on any further development on the matter by way of a further announcement(s) as and when necessary in accordance with the Catalist Rules.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants, or other professional advisers if they are in doubt about the actions that they should take.

**BY ORDER OF THE BOARD**

YEE PINH JEREMY  
Executive Director and Chief Executive Officer

22 August 2022

---

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the “**Sponsor**”), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist (“**Catalist Rules**”). This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*